Azienda Unita Sanitaria Locale Della Romagna

At Azienda Unita Sanitaria Locale Della Romagna in Faenza, the strongest research activity is centered on neoplasms and blood cancers. Trials span non-small cell lung cancer, breast cancer, colorectal cancer, ovarian cancer, and a wide range of lymphomas, leukemias, and multiple myeloma, reflecting a broad focus on improving treatment options for both solid and hematologic tumors.

• Testing new cancer therapies and combinations for advanced or difficult-to-treat tumors
• Evaluating approaches that improve survival, disease control, and recurrence prevention
• Studying personalized strategies for patients with specific tumor markers or genetic changes

This research portfolio includes efforts to refine immunotherapy, targeted treatment, and maintenance approaches, with the goal of making care more effective and better matched to each patient’s disease profile.

A major part of the site’s clinical trial activity involves respiratory tract diseases, especially lung cancer and chronic lung conditions such as idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The studies cover both early and advanced disease, with a strong emphasis on finding better ways to control progression and extend survival.

• Assessing new treatments for early-stage and metastatic lung cancer
• Exploring targeted and immune-based strategies for specific lung cancer subtypes
• Improving care for fibrotic lung disease through symptom and progression-focused research

This area shows a clear interest in treatments that can be used earlier in the disease course, as well as options for patients whose cancers carry actionable markers such as EGFR, ALK, or KRAS G12C.

The site also runs trials in cardiovascular diseases, including atrial fibrillation, heart failure, acute coronary syndrome, and prevention of ischemic stroke and venous thromboembolism. These studies aim to improve protection against serious cardiovascular events while balancing treatment safety.

• Evaluating therapies to reduce stroke risk in high-risk patients
• Studying treatment options for heart failure and inflammatory cardiovascular conditions
• Testing strategies to prevent clot-related complications in vulnerable populations

The cardiovascular portfolio complements the oncology program by addressing both chronic disease management and the prevention of life-threatening complications.

Beyond cancer, the research program includes immune system diseases, hemic and lymphatic diseases, and selected rare conditions such as systemic mastocytosis, myelofibrosis, paroxysmal nocturnal hemoglobinuria, and juvenile idiopathic arthritis. These trials focus on better disease control, symptom reduction, and safer long-term management.

• Studying new options for chronic blood and immune disorders
• Improving treatment for relapsed or hard-to-control hematologic diseases
• Exploring ways to reduce flares, inflammation, and disease-related complications

This part of the portfolio highlights the site’s experience in both common and uncommon conditions, including research aimed at supporting patients who need more individualized care.

A substantial number of studies at this site address digestive system diseases and gastrointestinal cancers such as colorectal cancer, gastric cancer, esophageal cancer, biliary tract cancer, and hepatocellular carcinoma. The main goal is to improve outcomes for patients with localized, advanced, or recurrent disease.

• Testing new combinations to improve tumor response and survival
• Evaluating perioperative and maintenance approaches after surgery or initial treatment
• Studying treatment strategies for cancers with limited standard options

These trials often focus on extending disease control and reducing the chance of recurrence, especially in patients with advanced gastrointestinal malignancies.

The site’s broader research also includes nervous system diseases, nutritional and metabolic diseases, and inflammatory conditions. Examples include multiple sclerosis, type 2 diabetes, and selected inflammatory or autoimmune disorders, showing that the research program extends beyond oncology into chronic disease management.

• Assessing therapies that may improve control of neurological disease activity
• Exploring treatments aimed at lowering inflammation and supporting metabolic health
• Investigating approaches that may improve long-term quality of life

Together, these studies reflect a site with a wide-ranging clinical trial profile, combining cancer research with important work in chronic medical conditions.